Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Capital Expenditures (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Capital Expenditures for 4 consecutive years, with $310000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures rose 355.88% to $310000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $562000.0, a 212.22% increase, with the full-year FY2024 number at $289000.0, up 270.51% from a year prior.
  • Capital Expenditures was $310000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $34000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $310000.0 in Q3 2025 to a low of -$3000.0 in Q4 2023.
  • A 4-year average of $94266.7 and a median of $54000.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 105.56% in 2023, then skyrocketed 3633.33% in 2024.
  • Orchestra BioMed Holdings' Capital Expenditures stood at $54000.0 in 2022, then plummeted by 105.56% to -$3000.0 in 2023, then surged by 3633.33% to $106000.0 in 2024, then skyrocketed by 192.45% to $310000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Capital Expenditures are $310000.0 (Q3 2025), $34000.0 (Q2 2025), and $112000.0 (Q1 2025).